Products

Services

Applications

Company

Complex Biology.

Clearer Answers.

Clinical diagnostics and research services spanning methylation, RNA, long-read genomics, bioinformatics, and assay development.

Start A Project

An Integrated Model for Impact

Renew builds platforms with a single goal: Improve patient care. With proprietary sequencing technologies and specialized analytical workflows, we uncover biological signals that conventional approaches often miss.

Our integrated technology model, which combines these workflows with CAP/CLIA laboratory infrastructure, transforms these molecular insights into real-world healthcare impact.

Contact

Clinical Products and Solutions

Renew translates advanced molecular technologies into clinical diagnostics, research tools, and operational workflows.

Clinical Product

NeuroLens®

Blood-based liquid biopsy for detecting neuron- and glia-associated cfDNA signals linked to active neurodegeneration.

QC Product

RNA Clarity™

Native RNA sequencing workflow for multi-attribute RNA therapeutic characterization, QC, and lot release testing.

Solution

Methylation Solutions

Native DNA methylation workflows enabling broader epigenetic coverage and higher-fidelity methylation profiling.

Solution

Hard-to-Sequence Genes

Long-read DNA sequencing workflows for resolving complex variants, repeats, haplotypes, and structural variation.

Built. Measured. Applied.

Green metallic 3D text showing the percentage 97.6%.

AUC - Alzheimer's disease discrimination in multi-disease cohorts

Green metallic text displaying the number and letter '30x'.

Increased CpG coverage compared to the Illumina Array

Shiny teal 3D style number 90 percent on black background.

Accuracy of long-read PGx panel for CYP2D6 of GIAB

Shiny teal 3D text displaying the number 99.1%.

Analytical Accuracy of cell classification for cfDNA diagnostic use cases

Glossy teal 97 percent symbol on a transparent background.

Regional methylation accuracy with targeted gDNA native-read sequencing

Turquoise 3D text showing greater than 90 percent symbol on black background.

Chromosome arms covered for reliable arm-level telomere length estimates

Scientist with a mask checking fluids in a lab

June 18, 2026

Renew Advances Epigenetic Diagnostics Through Path Fertility’s NOA Guide

Path Fertility’s NOA Guide uses epigenetic diagnostics to support surgical decision-making for non-obstructive azoospermia, with Renew as the clinical testing provider.

Text Link

June 18, 2026

Renew Expands Targeted Multiomic Sequencing Through Agilent Collaboration

Direct Targeted Methylation Sequencing combines Agilent enrichment with Renew’s native-read workflow to analyze genetic and epigenetic variation in targeted regions.

Text Link

June 18, 2026

Renew and Valinor Partner to Build Largest Clinical Multi-Omics Dataset for Neurology

Renew’s collaboration with Valinor combines high-resolution multiomic data generation and machine learning to support predictive model development in neurological disease research.

Text Link

June 18, 2026

Renew and Oxford Nanopore Accelerate Methylation Sequencing Toward Clinical Use

Renew and Oxford Nanopore are advancing Direct Whole Methylome Sequencing to capture genome-wide methylation, sequence, and hydroxymethylation signals.

Text Link

In The Press

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Working With The Best

Oxford Nanopore Technologies

Advancing Direct Whole Methylome Sequencing with Oxford Nanopore, a native-read approach designed to move methylation analysis beyond bisulfite sequencing and arrays.

Agilent Technologies

Direct Targeted Methylation Sequencing products and services combine Agilent enrichment with Renew’s native-read workflow for targeted genetic and epigenetic analysis.

Twist Bioscience

Custom hybridization panels developed with Twist support Oxford Nanopore-based long-read targeted sequencing for complex genomic regions and application-specific targets.

Boston Heart Diagnostics Partnership

A strategic distribution relationship with Boston Heart Diagnostics supports NeuroLens products and direct methylation sequencing services for blood-based brain cell death testing.

Questions & Answers

How can Renew's sequencing solutions support my research or project?

Renew delivers native-read, long-read sequencing to generate integrated genomic and epigenomic insights in single assays, supporting discovery, biomarker development, and scalable clinical translation.

Are Renew's NGS services suitable for clinical research?

Yes. Renew offers scalable, clinical-ready sequencing workflows designed for translational studies, cohort-scale research, and precision clinical testing, including platforms.

Is Renew’s clinical laboratory CLIA certified?

Yes. Renew is CLIA certified and CLEP- and FDA-ready. Our team supports programs from early discovery through clinical validation and patient testing, with expanding regulatory scope for IVDs, companion diagnostics, and global compliance (e.g., ISO 13485, ISO 15189, IVDR).

What NGS sequencing options are offered at Renew?

Renew offers whole-genome and targeted genomic, epigenomic, and transcriptomic sequencing using Oxford Nanopore technology, including Direct Whole Methylome Sequencing (dWMS), Direct Targeted Methylation Sequencing (dTMS), and standard ONT sequencing services.

How can I get started with Renew?

Explore our service offerings. For tailored research or development support, contact our team to discuss your project goals.

Discover Your Next Breakthrough